The tip of the TruScreen device has the opto-electrical hardware used to take a patient’s cervical tissue measurements.
A Single Use Sensor (SUS) is required for each patient examination. Its precision lens interacts with the tip of the device and cervix, protecting against cross-contamination.
The TruScreen Intelligent Cradle (IC) is the housing dock for the Handheld device. It charges the device and houses the Optical Test Plug.
The TruScreen Handheld Device has a built in LCD screen. The LCD guides the operator through the screening and provides the patient’s results at the end of the exam.
The portable Handheld Device is ergonomically designed to sit perfectly in the operators hand, it has an AI-enabled algorithm built in to processes the patient’s reading in real time.
Optical Test Plug (OTP) forms part of the system’s pre-screening self-check. It is used before each exam to ensure the device is performing optimally.
TruScreen is a real-time, objective, AI-enabled screening device. It is CE certified as a primary screening tool. TruScreen screens for the presence of pre-cancerous and cancerous tissue in the cervix.PRODUCT OVERVIEW
TruScreen’s technology is at the forefront of the development of object opto-electrical tissue differentiation and its key intellectual property is a protected trade secret. Over 23 man-years were spent on the development and testing of the AI-enabled algorithm.Development History
TruScreen’s cervical cancer screening device is certified for use throughout Europe, and NMPA approved for sale in China. It is currently available in multiple markets around the world through our distribution network.Markets and Distributors
Cervical cancer is the fourth most common cancer in women, with more than half a million women diagnosed with the disease in 2018. In low- and middle-income countries (LMIC’s) cervicalView
Cervical cancer affects millions of women worldwide. It is a silent killer, it has a high prevalence outside of developed countries, and almost all cases of cervical cancer can beView
Associate Professor Michael J. Campion, TruScreen Medical Advisory Committee member, sits down to discuss the science behind TruScreen’s Cervical Cancer Screening Device, its clinical validation, and its application in real-worldView
TruScreen’s breakthrough cervical cancer screening device is a viable and attractive alternative to traditional cervical screening methods. The TruScreen device resolves many of the ongoing issues associated with Pap tests,View
TruScreen CEO, Victoria Potarina, discusses the upcoming ASX dual listing and the accompanying IPO.View
“A novel diagnostic device for cervical cancer screening in India.”View
Our Russian distributor IntelMed Systems takes us into local hospitals where TruScreen pilot programmes are underway.View
The Market Herald Inview, TRU CEO Victoria PotarinaView
Zimbabwe may be known for its pristine wilderness, but it is also a country facing a major public health crisis in the form of high HIV and cervical cancer rates.View
Cervical cancer is an epidemic in India, with 77,300 new cases diagnosed each year and 37,800 deaths resulting from the disease—a fatality rate of 49 percent. About 160 million womenView
International Women’s Day is a global event marking the celebration of the social, economic, cultural and political achievements of women – while also making a call to action for acceleratingView
As announced last month, TruScreen's cervical cancer screening device was recognised in a joint publication that Unitaid has released with the World Health Organisation and the Clinton Health Access Initiative.View
Despite its rapidly growing economy, China remains a low- and middle-income nation. An example of this is its healthcare system. Although China has made impressive strides in improving healthcare accessView
Truscreen Group Limited (NZX/ASX: TRU) is pleased to provide a copy of its August 2021 Stakeholders Newsletter. This gives an update on TruScreen's performance and highlights key initiatives underway. HighlightsView
A new study, published in the European Journal of Obstetrics and Gynaecology and Reproductive Biology, concludes that TruScreen’s cervical cancer screening technology meets or exceeds the effectiveness of alternative cervicalView
TruScreen Group Limited is pleased to advise that it has received its first order from Serbia, Eastern Europe.View
Cervical cancer is one of the most preventable and treatable forms of cancer, yet over a quarter of a million women die from the disease each year. Ninety percent ofView
TruScreen Group Limited is pleased to announce the achievement of key milestones relating to the ongoing development of the Company’s women’s health care technology and its overseas growth strategy.View
The National Aids Council pilot will compare TruScreen to VIAC. VIAC is currently the common screening method for cervical cancer in the region. The NAC pilot hopes to have TruScreenView
In September 2021, TruScreen’s Russian distributor, Intelmed Systems, participated in the 15th annual “Wave of Health” initiative. The annual “Wave of Health” campaign sees a ship with teams of doctorsView